Myhas, also known as myosin heavy chain antisense long non-coding RNA, may be involved in regulating myosin heavy chain (MHC) gene expression. As natural antisense RNA transcripts (NATs), they potentially play a role in the coordinated shifts of MHC gene expression in human muscle in response to exercise training, such as the shift from IIx to IIa MHC [3].

In the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS), the progression of Myhas RNA levels across disease stages correlated with longevity, effectively discriminating between long-and short-term survival individuals, suggesting its potential as a prognostic indicator in ALS [1]. In laryngeal cancer, MYHAS appears to be a protective factor, and a 4-lncRNA signature including MYHAS can predict the prognosis of patients. Functional annotation analysis indicated that the mechanisms may involve the extracellular exosome, the Notch signaling pathway, voltage-gated calcium channels, and the Wnt signaling pathway [2].

In conclusion, Myhas plays a role in regulating MHC gene expression in response to exercise in humans. In disease models, it shows potential as a prognostic biomarker in ALS and as a protective factor in laryngeal cancer, highlighting its significance in understanding disease mechanisms and prognosis prediction.